

## Ethyol - (500 mg/Vial; Injectable, Injection)

|                              |   |                             |                      |
|------------------------------|---|-----------------------------|----------------------|
| <b>Generic Name</b>          | Amifostine  | <b>Innovator</b>            | CLINIGEN Health Care |
| <b>Dosage</b>                | 500 mg/Vial; Injectable, Injection  | <b>Branded US Sales</b>     | Less Than \$1000 mn  |
| <b>Probable FTF</b>          | Less Than 5   | <b>Known Para IV Filers</b> | Less Than 5          |
| <b>Other ANDA developers</b> | Less Than 5   | <b>Tentative Approvals</b>  | None                 |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | Less Than 5          |
| <b>Indication</b>            | Used to decrease the risk of kidney problems caused by treatment with a certain anti-cancer drug (cisplatin). It is also used to help prevent a certain side effect (dry mouth) caused by radiation treatment for head and neck cancer. |                             |                      |
| <b>Complexities</b>          | Yes   |                             |                      |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.